Pharmacokinetics, Safety and Bioequivalence of Levetiracetam Intravenous Infusion and Oral Tablets in Healthy Chinese Subjects

被引:12
|
作者
Toublanc, Nathalie [1 ]
Du, Xinlu [2 ]
Liu, Yun [3 ]
Chen, Qian [3 ]
Singh, Pritibha [4 ]
Chan, Robert [5 ]
Stockis, Armel [1 ]
机构
[1] UCB Pharma, B-1420 Braine Lalleud, Belgium
[2] UCB Pharma, Shanghai, Peoples R China
[3] Shanghai Xuhui Cent Hosp, Shanghai, Peoples R China
[4] UCB Pharma, Monheim, Germany
[5] UCB Pharma, Tokyo, Japan
关键词
DOSE PHARMACOKINETICS; PLACEBO;
D O I
10.1007/s40261-015-0303-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Objective Levetiracetam is available in China as adjunctive oral therapy for partial-onset seizures. This study was conducted to evaluate the bioequivalence between single-dose intravenous infusion and oral levetiracetam 1500 mg (Part A), and to assess the pharmacokinetics of multiple-dose intravenous infusion at the same dose (Part B) in healthy Chinese subjects. Methods Part A was an open-label, crossover comparison (intravenous vs. oral), while Part B was a double-blind, parallel-group study of intravenous levetiracetam versus intravenous placebo administered for 5 days. Results Bioequivalence was demonstrated between the 45-min intravenous infusion and oral tablets, with geometric mean area under the plasma concentration-time curve (AUC) from time 0 to infinity (AUC(infinity)) 492.3 and 506.8 mu g.h/mL, and geometric mean maximum concentration (C-max) 65.12 and 55.93 mu g/mL for intravenous infusion and oral dosing, respectively. Linear pharmacokinetics were demonstrated (geometric least-squares mean AUC during the dosing interval tau at steady state (AUC(tau,ss)) 475.6 mu g.h/mL; geometric least-squares mean AUC(infinity) after single dose 501.7 mu ga.h/mL; linearity factor = 0.948). Geometric mean C-max (77.44 mu g/mL) and AUC (tau,ss) (475.6 mu g.h/mL) of intravenous infusion levetiracetam 1500 mg after multiple doses were within the expected range, based on their respective single-dose values and the terminal half-life of levetiracetam after a single dose (7.13 h). A theoretical accumulation of approximately 40 % would be expected after multiple doses, which is consistent with the calculated accumulation of 18.0 and 43.5 % (R-max and R-AUC, respectively). Conclusions Intravenous infusion of levetiracetam is bioequivalent to oral levetiracetam in healthy Chinese subjects and is a suitable alternative for levetiracetam administration in patients who are temporarily unable to take their medication orally.
引用
收藏
页码:495 / 503
页数:9
相关论文
共 50 条
  • [1] Pharmacokinetics, Safety and Bioequivalence of Levetiracetam Intravenous Infusion and Oral Tablets in Healthy Chinese Subjects
    Nathalie Toublanc
    Xinlu Du
    Yun Liu
    Qian Chen
    Pritibha Singh
    Robert Chan
    Armel Stockis
    Clinical Drug Investigation, 2015, 35 : 495 - 503
  • [2] Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects
    Ramael, S
    De Smedt, F
    Toublanc, N
    Otoul, C
    Boulanger, P
    Riethuisen, JM
    Stockis, A
    CLINICAL THERAPEUTICS, 2006, 28 (05) : 734 - 744
  • [3] Pharmacokinetics, safety, and bioequivalence of apixaban tablets in healthy Chinese subjects under fasting and fed conditions
    Luo, Hong-Yu
    Yao, Zhen-Jiang
    Long, Hui-Zhi
    Zhou, Zi-Wei
    Xu, Shuo-Guo
    Li, Feng-Jiao
    Cheng, Yan
    Wen, Dan -Dan
    Deng, Ping
    Guan, Yue-Qing
    Gao, Li-Chen
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2023, 61 (03) : 129 - 138
  • [4] Pharmacokinetics and bioequivalence studies of fluvoxamine maleate tablets in healthy Chinese subjects
    She, Ding-ping
    He, Ying
    Li, Ming-qu
    Su, Li
    Ren, Di
    Huang, Xiao-han
    Zhang, Yu-Hua
    Hu, Hai-tang
    Deng, De-cheng
    Wu, Jian-long
    BIOMEDICAL CHROMATOGRAPHY, 2023, 37 (06)
  • [5] Pharmacokinetics and safety of repirinast tablets in healthy Chinese subjects
    Lv, Cheng-Zhe
    Huang, Ming
    Zhang, Quan-Ying
    Zong, Shun-Lin
    Wang, Meng
    BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 54 (02)
  • [6] Pharmacokinetics, Bioequivalence, and Safety Studies of Prucalopride in Healthy Chinese Subjects
    Zhou, Ziye
    Wang, Chenxiang
    Zheng, Xuyong
    Yu, Xuben
    Yu, Chao
    Zhang, Dongchuan
    Xia, Yan
    Chen, Huafang
    Huang, Xiaoxiao
    Zhang, Xiuhua
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (06): : 671 - 676
  • [7] A crossover study to evaluate the pharmacokinetics and bioequivalence of hydroxychloroquine tablets in healthy Chinese subjects
    Feng, Jie
    Kuang, Shuang-yu
    Wan, Jun-han
    Li, Rong
    Zhu, Yi-jie
    Cai, Bei-lei
    Guan, Lei
    Zhang, Zheng
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2024, 62 (06) : 284 - 292
  • [8] Safety, tolerability and pharmacokinetics of levetiracetam intravenous infusion
    Stockis, A.
    Toublanc, N.
    Ramael, S.
    De Smedt, F.
    Otoul, C.
    Boulanger, P.
    Riethuisen, J. M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 : 232 - 232
  • [9] Safety, tolerability, and pharmacokinetics of levetiracetam intravenous infusion
    Stockis, A.
    Toublanc, N.
    Ramael, S.
    De Smedt, F.
    Otoul, C.
    Boulanger, P.
    Riethuisen, J.
    EPILEPSIA, 2007, 48 : 107 - 108
  • [10] Pharmacokinetics and Bioequivalence of 2 Oral Formulations of Vildagliptin in Healthy Chinese Subjects
    Tian, Mengli
    Ye, Libing
    Liang, Binhong
    Chen, Yingrong
    Mei, Jue
    Zhao, Zhouming
    Guo, Xiaodi
    Xu, Min
    Zhang, Jingyao
    Yang, Shuixin
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2025, 14 (02): : 154 - 160